ARWR vs. ULS
ARWR (Arrowhead Pharmaceuticals, Inc.) and ULS (UL Solutions Inc) are both stocks. ARWR operates in Biotechnology (Healthcare), while ULS operates in Specialty Business Services (Industrials). Over the past year, ARWR returned 435.25% vs 27.90% for ULS. At a 0.16 correlation, their price movements are largely independent.
Performance
ARWR vs. ULS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ARWR achieves a 23.51% return, which is significantly higher than ULS's 14.12% return.
ARWR
- 1D
- 0.22%
- 1M
- 9.41%
- YTD
- 23.51%
- 6M
- 18.84%
- 1Y
- 435.25%
- 3Y*
- 32.51%
- 5Y*
- -1.42%
- 10Y*
- 31.09%
ULS
- 1D
- -1.78%
- 1M
- -12.65%
- YTD
- 14.12%
- 6M
- 15.51%
- 1Y
- 27.90%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
ARWR vs. ULS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
ARWR Arrowhead Pharmaceuticals, Inc. | 23.51% | 253.14% | -26.79% |
ULS UL Solutions Inc | 14.12% | 59.33% | 46.87% |
Correlation
The correlation between ARWR and ULS is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Apr 12, 2024 | 0.16 |
Fundamentals
ARWR:
$11.68B
ULS:
$18.30B
ARWR:
-$2.16
ULS:
$1.71
ARWR:
18.39
ULS:
5.88
ARWR:
19.50
ULS:
13.70
ARWR:
$622.01M
ULS:
$3.11B
ARWR:
$529.27M
ULS:
$1.54B
ARWR:
-$168.38M
ULS:
$725.35M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARWR vs. ULS — Risk / Return Rank
ARWR
ULS
ARWR vs. ULS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and UL Solutions Inc (ULS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARWR | ULS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +6.04 | ||
| Sortino ratioReturn per unit of downside risk | +4.00 | ||
| Omega ratioGain probability vs. loss probability | 1.68 | 1.17 | +0.51 |
| Calmar ratioReturn relative to maximum drawdown | 17.81 | 1.15 | +16.66 |
| Martin ratioReturn relative to average drawdown | 49.05 | 2.88 | +46.18 |
Loading charts...
Drawdowns
ARWR vs. ULS - Drawdown Comparison
The maximum ARWR drawdown since its inception was -99.24%, which is greater than ULS's maximum drawdown of -24.34%. Use the drawdown chart below to compare losses from any high point for ARWR and ULS.
Loading charts...
Drawdown Indicators
| ARWR | ULS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.24% | -24.34% | -74.90% |
Max Drawdown (1Y)Largest decline over 1 year | -24.64% | -24.34% | -0.30% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -88.94% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -88.96% | — | — |
Current DrawdownCurrent decline from peak | -49.54% | -14.35% | -35.19% |
Average DrawdownAverage peak-to-trough decline | -81.19% | -5.63% | -75.56% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.93% | 9.72% | -0.79% |
Volatility
ARWR vs. ULS - Volatility Comparison
Arrowhead Pharmaceuticals, Inc. (ARWR) has a higher volatility of 14.13% compared to UL Solutions Inc (ULS) at 6.02%. This indicates that ARWR's price experiences larger fluctuations and is considered to be riskier than ULS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ARWR | ULS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.13% | 6.02% | +8.11% |
Volatility (6M)Calculated over the trailing 6-month period | 36.34% | 30.40% | +5.94% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.46% | 41.58% | +23.88% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 65.02% | 35.68% | +29.34% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.19% | 35.68% | +38.51% |
Dividends
ARWR vs. ULS - Dividend Comparison
ARWR has not paid dividends to shareholders, while ULS's dividend yield for the trailing twelve months is around 0.61%.
| Position | TTM | 2025 | 2024 |
|---|---|---|---|
ARWR Arrowhead Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% |
ULS UL Solutions Inc | 0.61% | 0.66% | 0.75% |
Financials
ARWR vs. ULS - Financials Comparison
This section allows you to compare key financial metrics between Arrowhead Pharmaceuticals, Inc. and UL Solutions Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ARWR and ULS have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ARWR has higher volatility (14.13%) compared to ULS (6.02%). In terms of maximum drawdown, ARWR dropped -99.24% vs ULS's -24.34%.
ARWR currently has the higher Sharpe Ratio (6.72 vs 0.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ARWR and ULS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer